Sino Biological

What Sino Biological does

Sino Biological, Inc. is a Beijing-headquartered, Shenzhen Stock Exchange-listed (301047.SZ) biotechnology company founded in 2007 that develops, manufactures, and distributes recombinant proteins, antibodies, ELISA kits, viral antigens, cDNA clones, and cell-free protein synthesis reagents for the global life sciences research market. Its technology platform spans multiple expression systems (E. coli, HEK293, CHO, Baculovirus-Insect) plus proprietary cell-free synthesis (XPressMAX™), endotoxin-free protein production at a Houston Center for Bioprocessing (ProPure™), five antibody discovery platforms (Beacon® single B cell, FACS, phage display, hybridoma, rabbit pAb), and a 1,100+ kinase portfolio acquired through the April 2024 purchase of SignalChem Biotech for $48 million USD. The company also offers GMP-grade cytokines and a growing menu of CRO services spanning high-throughput antibody production, cell-free protein expression, multi-pass transmembrane protein development, and ADC/CAR-T/organoid solution workflows.

The company monetizes through a hybrid catalog-plus-CRO model: one-time catalog purchases of off-the-shelf reagents priced at unit economics with promotional discounting, paired with quote-based CRO services covering expression, purification, antibody development, and kinase assay/screening at scales from micrograms to kilograms. Distribution combines direct e-commerce and field sales in the US (Houston and Paoli), Europe (Eschborn, Germany), Japan (Kawasaki), and South Korea (Seoul) with a distributor network covering 50+ additional countries, serving academic institutions, biotechnology companies, and pharmaceutical organizations in over 90 countries. Compliance posture includes ISO 9001, ISO 13485, GMP, CMA, and CNAS certifications, with FDA DMF filing available for GMP-grade cytokines, enabling progression up the value chain from research-use-only reagents toward clinical and cell-therapy manufacturing customers.

Name

Sino Biological

Legal name

Sino Biological, Inc.

Website

https://sinobiological.com

Company type

Public

Founded year

2007

Operating status

Operating

Headcount range

251–500 employees

Short description

Sino Biological is a Beijing-based, Shenzhen-listed (301047.SZ) biotechnology company that develops and distributes recombinant proteins, antibodies, ELISA kits, and CRO services for life sciences research and drug discovery customers across more than 90 countries.

Ownership category

akta.pro rank

Product category

Life Science Reagents

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes) (HLAGAIAI)

akta.pro secondary industries

Bioprocess Consumables & Reagents (resins, membranes, media components, buffers) (HLAAAJAI), Analytical Development & QC Testing (Release/Stability/Potency) (HLAGAGAF)

Keywords

• Recombinant proteins
• Monoclonal antibodies
• Cell-free protein synthesis
• Kinase reagents
• CRO services

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Recombinant Protein and Antibody Catalog Sales: Sale of catalog products including recombinant proteins, antibodies, cDNA clones, ELISA kits, and cell culture media. Products sold directly through website and via global distributor network.
2. CRO Services: Contract research organization services including recombinant protein expression, antibody production, assay development, and compound screening. Services range from high-throughput screening to large-scale production (μg to kg scale).
3. Cell-Free Protein Synthesis Kits: Sale of XPressMAX™ Cell-Free Protein Synthesis Kit and related reagents for high-throughput protein expression.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels7 records

Core offering

Sino Biological manufactures and sells recombinant proteins, antibodies, ELISA kits, kinases, and related bioreagents through a catalog of over 77,000 products, and provides CRO services for antibody development, protein expression, and drug discovery. The company also operates proprietary cell-free protein synthesis (XPressMAX), endotoxin-free protein production (ProPure), and a kinase portfolio acquired via SignalChem, serving life sciences researchers in over 90 countries.

Product overview

Sino Biological is a global life science reagent provider and CRO services company offering a comprehensive portfolio of recombinant proteins, antibodies, and custom services. The core offerings include the XPressMAX™ Cell-Free Protein Synthesis Kit for ultra-fast protein production in 3 hours, ProPure™ Endotoxin-Free Proteins achieving <0.05 EU/mg endotoxin levels, and the largest recombinant Tau protein library. The company operates the SignalChem Biotech kinase portfolio (acquired 2024) providing 1,100+ highly active kinases, along with ELISA/ELISpot assay kits, SwiftFluo® TR-FRET kinase assays, GMP-grade cytokines, and site-specifically labeled proteins. CRO services span antibody development (recombinant, humanization, bispecific), protein expression (mammalian, baculovirus, bacterial, cell-free), single B cell screening (Beacon®, FACS), and specialized services for ADC, CAR-T/CAR-NK, and organoid research. The company operates production facilities in Beijing, Houston (Center for Bioprocessing), Vancouver (SignalChem), and European operations in Germany, serving researchers in over 90 countries.

Differentiator

Problem solved

Functional benefit

Brands

• ProPure™: Endotoxin-free recombinant proteins product line achieving endotoxin levels below 0.05 EU/mg, produced at the Center for Bioprocessing in Texas. Used for preclinical studies, animal immunization, cell-based assays, and sensitive biopharmaceutical applications.
• XPressMAX™
• EliteRmab®
• SwiftFluo®
• Center for Bioprocessing (C4B)
• ProVir®

Products and services

• XPressMAX Cell-Free Protein Synthesis Kit Ultra-fast cell-free protein synthesis kit enabling protein and antibody expression in approximately 3 hours with greater than 99% success rate. Uses optimized E. coli lysates and supports plasmid and linear DNA templates, disulfide bonding, and high-throughput screening for VHH, scFv, Fab, and miniproteins, targeting researchers using AI-driven antibody design.
• ProPure Endotoxin-Free Proteins Endotoxin-free recombinant proteins produced at the Center for Bioprocessing in Texas, achieving endotoxin levels below 0.05 EU/mg (10x below the USP <85> standard of 0.5 EU/mg). Covers ADC targets, cell therapy-related proteins, immune checkpoints, cytokines, and viral antigens for preclinical studies, animal immunization, and cell-based assays.
• Tau Proteins World's largest recombinant Tau protein library featuring diverse isoforms (0N3R, 1N3R, 2N3R, 0N4R, 1N4R, 2N4R), kinase-phosphorylated Tau proteins, Tau mutants (including P301L, P301S), and biotinylated Tau proteins for neurodegenerative disease research.
• Recombinant Proteins Comprehensive catalog of recombinant proteins including cytokines, growth factors, immune checkpoint proteins, enzymes, Fc receptors, signaling proteins, transmembrane proteins, viral antigens, and therapeutic targets, available in multiple expression systems (E. coli, HEK293, CHO, Baculovirus-Insect).
• Antibodies Broad portfolio of antibodies including EliteRmab rabbit monoclonal antibodies, phospho-specific antibodies, primary antibodies, neutralizing antibodies, virus antibodies, control antibodies, and research-grade biosimilar antibodies for various research applications.
• SignalChem Biotech Kinase Portfolio Following the 2024 acquisition, SignalChem Biotech offers 1,100+ highly active kinases covering more than 90% of the human kinome, 400+ clinically relevant mutant kinases, custom enzyme and assay development, and compound screening/profiling services cited in 2,000+ customer publications.
• ELISA Kits and ELISpot Assay Kits High-quality ELISA kits for cytokine quantification (IFN-gamma, TNF-alpha, IL-2, IL-4, IL-6) and ELISpot detection kits with sensitivity for single-cell detection and ready-to-use pre-coated plates for vaccine development and drug screening.
• SwiftFluo TR-FRET Kinase Assay Kits Ready-to-use time-resolved fluorescence resonance energy transfer (TR-FRET) kits for high-throughput screening of kinase inhibitors, profiling over 60 tyrosine kinases, 150 serine/threonine kinases, and 15 cyclin-dependent kinases.
• GMP-grade Cytokines Good Manufacturing Practice grade cytokines including EGF, Activin A, and others with ISO 9001, ISO 13485, and GMP certification, FDA DMF filing available, suitable for cell therapy manufacturing and clinical applications.
• Beacon Single B Cell Screening CRO Service Single B cell discovery CRO service enabling obtainment of positive clones within 35 days with 99.5% monoclonality rate for antibody discovery campaigns.
• Cell-Free Protein Expression CRO Service Contract research service using cell-free expression technology delivering proteins in as fast as 5 days with greater than 99% success rate for high-throughput antibody discovery and protein production.
• High-Throughput Antibody Production CRO Service Recombinant antibody production service from gene to purified antibody in as fast as 10 days, supporting more than 10,000 antibodies per month in formats including IgG, bispecific antibodies, VHH, and scFv.
• ProPure Endotoxin-Free Protein Expression CRO Service Custom endotoxin-free protein expression service at Center for Bioprocessing (C4B) in Texas using mammalian expression systems (HEK293, ExpiCHO) achieving greater than 90% purity and endotoxin levels below 0.05 EU/mg with delivery in as fast as 2 weeks.
• Multi-pass Transmembrane Protein Development CRO Service Specialized service for expression and purification of challenging multi-pass transmembrane proteins using VLP-based technology platform for drug discovery and structural biology applications.
• ProVir Viral Reagent Bank Comprehensive viral reagent collection covering more than 50 viruses including influenza, SARS-CoV-2 variants, RSV, MPXV, Nipah virus, herpes virus, VZV, RABV, HPV, Hantavirus, and CHIKV for infectious disease research, vaccine development, and diagnostic applications.
• Site-specifically Labeled Proteins Proteins with site-specific labeling (biotin, fluorophores) for precise detection and quantification in assay development, with consistent labeling efficiency and retention of biological activity.
• Influenza Vaccine Strain Antigens 2026-2027 Recombinant antigens for the 2026-2027 Northern Hemisphere influenza vaccine strains following WHO recommendations, covering H1N1 (A/Missouri/11/2025), H3N2 subclade K, and B/Victoria lineage strains to support global flu vaccine development.
• Anti-G4S and Anti-Whitlow/218 Linker Rabbit mAbs (CAR Linker Antibodies) Universal CAR detection antibodies specifically binding to G4S or Whitlow/218 linkers between heavy and light chains of scFv fragments, available in multiple conjugates (FITC, PE, APC, AF488, AF647, Biotin) for flow cytometry applications across CAR-T development workflows.
• EliteScience VIP Partnership Program Premium partnership service program for European researchers offering prioritized production and shipping, risk-free CRO services with a no-results-no-fee policy, and priority access to more than 77,000 in-stock reagent samples, including 24-hour local technical assistance.

Quantifiable outcome

• Protein synthesis in 3 hours with >99% success rate
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature5 records

Partnerships

One partnership is on record.

• SignalChem Biotech Inc.coreStrategic or Co-development Partner · 27 April 2024Sino Biological finalized acquisition of Vancouver-based SignalChem Biotech Inc. for $48 million USD, making it a wholly-owned subsidiary. The acquisition enhances Sino Biological's enzyme production capabilities and broadens its technology platform for life sciences research and drug discovery. SignalChem brings expertise in bioactive enzymes, 1,100+ highly active kinases, and 400+ clinically relevant mutant kinases.

Scale indicators15 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Bio-Techne: Direct competitor in recombinant proteins, antibodies, ELISA kits, and cytokines (R&D Systems brand). Most comparable public peer for Sino Biological's core catalog and CRO services.
• GenScript: Direct competitor headquartered in New Jersey with major operations in China. Offers gene synthesis, recombinant proteins, antibodies, and CRO services — virtually identical product set to Sino Biological.
• ACROBiosystems: Direct competitor in recombinant proteins, especially for biologics, bispecific antibodies, and cell therapy targets. Closest pure-play peer given similar China-rooted operations and biopharma-focused catalog.
• Abcam: Direct peer in research-use antibodies and related reagents (now part of Danaher). Comparable catalog breadth and academic/biopharma customer overlap with Sino Biological's antibody business.
• Cell Signaling Technology: Direct peer in signaling-pathway antibodies, phospho-specific reagents, and kinase-related tools. Overlaps with Sino Biological's kinase portfolio (SignalChem) and signaling protein catalog.
• PeproTech: Specialist in recombinant cytokines and growth factors, now part of Thermo Fisher. Overlaps directly with Sino Biological's cytokine catalog and GMP-grade cytokine positioning.

Broad incumbents

• Thermo Fisher Scientific: Broad life sciences incumbent (Gibco, Invitrogen, Thermo Scientific brands) offering proteins, antibodies, and CRO services as part of a much larger portfolio. Key competitive constraint on Sino Biological's enterprise wins.
• Bio-Rad Laboratories: Broad incumbent in life science research reagents, including antibodies, proteins, and instrumentation. Competes with Sino Biological across multiple product lines but as one of many priorities.

Emerging players

• Miltenyi Biotec: Privately-held peer with strong positions in cell/gene therapy reagents and flow cytometry antibodies. Emerging competitor in adjacent CAR-T and cell therapy reagent markets where Sino Biological is also investing.
• Repligen: Specialist in bioprocessing and biomanufacturing consumables including proteins, enzymes, and chromatography reagents. Comparable in bioprocess reagent focus but with stronger upstream biomanufacturing positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/sinobiological
• Facebookfacebook.com/sinobiological
• LinkedInlinkedin.com/company/sino-biological-inc

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries5 records

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sino Biological